Clinical trial
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
NCT06958211 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
- Lead sponsor
- Incyte Corporation
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- June 12, 2025
- Completion date
- July 11, 2027
- Enrollment
- 573 (actual)
- Sites
- 107
Conditions
As the registry lists them; a condition with its own page is linked.